Literature DB >> 31238088

Four-repeat tauopathies.

Thomas W Rösler1, Amir Tayaranian Marvian1, Matthias Brendel2, Niko-Petteri Nykänen3, Matthias Höllerhage1, Sigrid C Schwarz3, Franziska Hopfner4, Thomas Koeglsperger5, Gesine Respondek1, Kerstin Schweyer1, Johannes Levin5, Victor L Villemagne6, Henryk Barthel7, Osama Sabri7, Ulrich Müller8, Wassilios G Meissner9, Gabor G Kovacs10, Günter U Höglinger11.   

Abstract

Tau is a microtubule-associated protein with versatile functions in the dynamic assembly of the neuronal cytoskeleton. Four-repeat (4R-) tauopathies are a group of neurodegenerative diseases defined by cytoplasmic inclusions predominantly composed of tau protein isoforms with four microtubule-binding domains. Progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease or glial globular tauopathy belong to the group of 4R-tauopathies. The present review provides an introduction in the current concept of 4R-tauopathies, including an overview of the neuropathological and clinical spectrum of these diseases. It describes the genetic and environmental etiological factors, as well as the contemporary knowledge about the pathophysiological mechanisms, including post-translational modifications, aggregation and fragmentation of tau, as well as the role of protein degradation mechanisms. Furthermore, current theories about disease propagation are discussed, involving different extracellular tau species and their cellular release and uptake mechanisms. Finally, molecular diagnostic tools for 4R-tauopathies, including tau-PET and fluid biomarkers, and investigational therapeutic strategies are presented. In summary, we report on 4R-tauopathies as overarching disease concept based on a shared pathophysiological concept, and highlight the challenges and opportunities on the way towards a causal therapy.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  4R-tauopathy; Alzheimer’s disease; Argyrophilic grain disease; Corticobasal degeneration; Glial globular tauopathy; Microtubule-Associated protein tau; Progressive supranuclear palsy

Mesh:

Substances:

Year:  2019        PMID: 31238088     DOI: 10.1016/j.pneurobio.2019.101644

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  41 in total

1.  Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies.

Authors:  Gesine Respondek; Max-Joseph Grimm; Ines Piot; Thomas Arzberger; Yaroslau Compta; Elisabet Englund; Leslie W Ferguson; Ellen Gelpi; Sigrun Roeber; Armin Giese; Murray Grossman; David J Irwin; Wassilios G Meissner; Christer Nilsson; Alexander Pantelyat; Alex Rajput; John C van Swieten; Claire Troakes; Günter U Höglinger
Journal:  Mov Disord       Date:  2019-09-30       Impact factor: 10.338

2.  Additive value of [18F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome.

Authors:  Sabrina Katzdobler; Alexander Nitschmann; Johannes Levin; Matthias Brendel; Henryk Barthel; Gerard Bischof; Leonie Beyer; Ken Marek; Mengmeng Song; Olivia Wagemann; Carla Palleis; Endy Weidinger; Anne Nack; Urban Fietzek; Carolin Kurz; Jan Häckert; Theresa Stapf; Christian Ferschmann; Maximilian Scheifele; Florian Eckenweber; Gloria Biechele; Nicolai Franzmeier; Anna Dewenter; Sonja Schönecker; Dorothee Saur; Matthias L Schroeter; Jost-Julian Rumpf; Michael Rullmann; Andreas Schildan; Marianne Patt; Andrew W Stephens; Thilo van Eimeren; Bernd Neumaier; Alexander Drzezga; Adrian Danek; Joseph Classen; Katharina Bürger; Daniel Janowitz; Boris-Stephan Rauchmann; Sophia Stöcklein; Robert Perneczky; Florian Schöberl; Andreas Zwergal; Günter U Höglinger; Peter Bartenstein; Victor Villemagne; John Seibyl; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-09-14       Impact factor: 10.057

3.  Non-invasive and high-throughput interrogation of exon-specific isoform expression.

Authors:  Dong-Jiunn Jeffery Truong; Teeradon Phlairaharn; Bianca Eßwein; Christoph Gruber; Deniz Tümen; Enikő Baligács; Niklas Armbrust; Francesco Leandro Vaccaro; Eva-Maria Lederer; Eva Magdalena Beck; Julian Geilenkeuser; Simone Göppert; Luisa Krumwiede; Christian Grätz; Gerald Raffl; Dominic Schwarz; Martin Zirngibl; Milica Živanić; Maren Beyer; Johann Dietmar Körner; Tobias Santl; Valentin Evsyukov; Tabea Strauß; Sigrid C Schwarz; Günter U Höglinger; Peter Heutink; Sebastian Doll; Marcus Conrad; Florian Giesert; Wolfgang Wurst; Gil Gregor Westmeyer
Journal:  Nat Cell Biol       Date:  2021-06-03       Impact factor: 28.824

Review 4.  Zebrafish Models to Study New Pathways in Tauopathies.

Authors:  Clément Barbereau; Nicolas Cubedo; Tangui Maurice; Mireille Rossel
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

5.  Clinical Features Observed in General Practice Associated With the Subsequent Diagnosis of Progressive Supranuclear Palsy.

Authors:  Mary J Kwasny; Denise M Oleske; Jorge Zamudio; Robert Diegidio; Günter U Höglinger
Journal:  Front Neurol       Date:  2021-04-22       Impact factor: 4.003

Review 6.  Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies.

Authors:  Maria Stamelou; Gesine Respondek; Nikolaos Giagkou; Jennifer L Whitwell; Gabor G Kovacs; Günter U Höglinger
Journal:  Nat Rev Neurol       Date:  2021-08-23       Impact factor: 42.937

7.  Radiosynthesis, In Vitro and In Vivo Evaluation of [18F]CBD-2115 as a First-in-Class Radiotracer for Imaging 4R-Tauopathies.

Authors:  Anton Lindberg; Ashley C Knight; Daniel Sohn; Laszlo Rakos; Junchao Tong; April Radelet; N Scott Mason; Jeffrey S Stehouwer; Brian J Lopresti; William E Klunk; Johan Sandell; Alexander Sandberg; Per Hammarström; Samuel Svensson; Chester A Mathis; Neil Vasdev
Journal:  ACS Chem Neurosci       Date:  2021-01-26       Impact factor: 5.780

Review 8.  Four-Repeat Tauopathies: Current Management and Future Treatments.

Authors:  Lawren VandeVrede; Peter A Ljubenkov; Julio C Rojas; Ariane E Welch; Adam L Boxer
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

9.  Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database.

Authors:  Emma Viscidi; Irene Litvan; Tien Dam; Maneesh Juneja; Li Li; Henry Krzywy; Susan Eaton; Susan Hall; Joseph Kupferman; Günter U Höglinger
Journal:  Front Neurol       Date:  2021-06-17       Impact factor: 4.003

10.  In vivo coupling of dendritic complexity with presynaptic density in primary tauopathies.

Authors:  Elijah Mak; Negin Holland; P Simon Jones; George Savulich; Audrey Low; Maura Malpetti; Sanne S Kaalund; Luca Passamonti; Timothy Rittman; Rafael Romero-Garcia; Roido Manavaki; Guy B Williams; Young T Hong; Tim D Fryer; Franklin I Aigbirhio; John T O'Brien; James B Rowe
Journal:  Neurobiol Aging       Date:  2021-01-30       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.